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words. Of these, 32 studies met the inclusion criteria. Studies indicate that pancreatic 
cancer has an extremely poor prognosis: for all stages combined, the 1- and 5-year 
relative survival rates are 25% and 6%, respectively. Pancreatic cancer is the fourth 
most common cause of cancer-related deaths in the United States and the eighth 
worldwide. More than 50% of patients come to clinical attention with metastatic 
disease, and an additional 30%–40% present with locally advanced tumors. Current 
treatments include surgery and palliative chemotherapy such as gemicitabine and 
gemcitabine/erlotinib combination. Recently nab-paxclitacel was approved based on 
a 1.8 month improvement in the overall survival. ConClusions: This systematic 
review shows that patients with pancreatic cancer have a very low survival rate. There 
is an urgent need for new treatments for these patients.
PCN57
The effeCT Of MeTfOrMiN Use ANd MOrTAliTy AMONg ThOse WiTh 
PANCreATiC CANCer ANd TyPe 2 diAbeTes MelliTUs: fiNdiNgs frOM A 
NATiONWide POPUlATiON reTrOsPeCTive COhOrT sTUdy
Jo A1, Kim Y1, Kang S1, Kim M2, Ko M1
1National Evidence based Health-care Collaborating Agency, Seoul, South Korea, 2Korea Institute 
of Radiological & Medical Sciences, Seoul, South Korea
objeCtives: This study evaluated the effect of metformin use on survival in 
pancreatic cancer patients with curative resection and type 2 diabetes mellitus 
(T2DM). Methods: A total of 28,862 were initially identified from Korea Center 
Cancer Registry (KCCR) who had diagnostic code for pancreatic carcinoma between 
1 January 2005 and 31 December 2011. Among them, those with curative resec-
tion or T2DM and aged over 40 years were included. Subjects were classified as 
metformin user group if they were prescribed metformin around the time of diag-
nosis for pancreatic cancer. Medication possession ratio (MPR) of more than 80% 
was considered as acceptable adherence. Survival from pancreatic carcinoma was 
identified from the linkage of National Population Registry of the Korea National 
Statistical Office with KCCR through December 31, 2013. Several sensitivity analyses 
were performed to examine the effect of immortal time bias, and confounding vari-
ables. Results: The study included 764 subjects with T2D and pancreatic cancer 
with curative resection, 530 of which were exposed to metformin. In multivariable 
analysis, the adjusted risk for pancreatic cancer specific mortality of metformin 
user was significantly lower than that of metformin non-user (hazard ratio, 0.73; 
95% CI, 0.61 to 0.87; P < 0.001). The adjusted risk for mortality was also significantly 
lower in MPR of more than 80% compared with that of MPR of less than 80% (HR, 
0.60, 95% CI: 0.47-0.76, p-value< 0.001). In addition, similar results were found from 
a serial of seneitivity analysis. ConClusions: Metformin use in diabetic patients 
with pancreatic cancer is associated with improved survival. This may provide a 
rationale for further prospective study of the use of metformin as an adjunct to the 
standard of care in the treatment of pancreatic cancer.
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sTATiNs Use ANd The risk Of heMATOlOgiCAl ANd NON-heMATOlOgiCAl 
MAligNANCies: A MeTA-ANAlysis Of 53 ObservATiONAl sTUdies
Bhutani MK, Rai MK, Kaneria J, Goyal R, Kumar R, Raute L
Tata Consultancy Services, Mumbai, India
objeCtives: Statins are frequently prescribed drugs worldwide, used for the 
management and prevention of coronary artery diseases. In contrast to early 
concerns over carcinogenicity of statins, recent evidences suggest that statins 
may have chemo-preventive potential against variety of cancers. We performed a 
detailed meta-analysis of observation studies to quantify the association between 
statins and risk of cancers. Methods: A comprehensive search was performed in 
EMBASE®/Cochrane/Pubmed to retrieve studies investigating association of statins 
and hematological and non-hematological cancers (prostate, breast, lung, and colo-
rectal). The studies were screened and abstracted by two independent reviewers. 
The studies were assessed for heterogeneity and pooled relative risks and 95% CIs 
were calculated using fixed effect and random effect models. Results: Of the 
4500 retrieved articles, 53 observational studies (27 case control and 26 cohort) 
contributed to analysis. The use of statins had modest chemo-protective potential 
against non-hematological cancers (prostate, breast, lung, and colorectal taken alto-
gether). However, the association did not reach statistical significance (RR= 0.93; 
95% CI, 0.87 to 1.0, p= 0.09). There was no significant association between statins 
use and risk of prostate (RR= 0.93; 95% CI, 0.79 to 1.09, p= 0.16), breast (RR= 0.97; 95% 
CI, 0.91 to 1.03, p= 0.3), lung (RR= 0.90; 95% CI, 0.75 to 1.08, p= 0.25), and colorectal 
cancer (RR= 0.94; 95% CI, 0.88 to 1.0, p= 0.06). In contrast, statins use was associated 
with significant reduction in risk of hematological malignancies (RR= 0.82; 95% CI, 
0.67 to 0.99, p= 0.04). Following the statins use, risk of non-hodgkin’s lymphoma 
(RR= 0.69; 95% CI, 0.49 to 0.96, p= 0.03) was reduced whereas no association was 
observed with lymphoma (RR= 0.99; 95% CI, 0.37 to 2.69, p= 0.99). ConClusions: 
Our meta-analysis results demonstrated that statins were associated with a mod-
est reduction in risk of non-hematological cancers, when taken for management 
of hypercholesterolemia. On the contrary, statins demonstrated chemo-protective 
potential against risk of hematological malignancies.
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AdjUsTiNg fOr CrOss-Over iN ONCOlOgy TriAls: APPrOAChes TAkeN TO 
sUPPOrT drUg reiMbUrseMeNT iN AUsTrAliA
O’Leary BA1, Gordois AL1, McElroy H2
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objeCtives: Trials of new oncology treatments often allow patients to crossover 
from control to experimental treatment either at disease progression or a specific 
time point. If crossover occurs after progression, progression free survival is largely 
unaffected; however overall survival (OS) is confounded in the control arm. Patients 
switching treatments often have different prognoses, resulting in a biased estimated 
OS difference. Advanced statistical methods to adjust for crossover include Rank 
Preserving Structural Failure Time (RPSFT) models, Inverse Probability of Censoring 
[IQR: $13,220-38,966]). Adjusting for patient and facility characteristics, total 
charges for lung ($ 2396, p= 0.03), colorectal ($10,844, p< 0.0001), and pancreatic 
cancers ($ 7504, p< 0.0001) were significantly higher than liver cancers. Significant 
predictors of LOS included race/ethnicity (compared to whites, 15% longer for 
blacks (IRR= 1.15, 95% CI: 1.13-1.17 ) and 4% longer for Hispanics (IRR= 1.04, 95% 
CI: 1.02-1.06) and hospital location (compared to rural hospitals, 12% longer for 
non-teaching urban (IRR= 1.12, 95% CI: 1.10-1.14) and 15% longer for teaching urban 
(IRR= 1.15, 95% CI: 1.13-1.17). ConClusions: We found significant differences in 
proportion of hospitalizations, LOS, and charges between cancer types, moderated 
by patient and facility characteristics. Of the cancer sites considered, liver cancers 
had the lowest incidence of hospitalization, shortest LOS, and lowest total charges.
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AssessMeNT Of reNAl fUNCTiON AMONg PATieNTs WiTh bONe 
MeTAsTAses frOM sOlid TUMOrs
Qian Y1, Bhowmik D1, Bond TC2, Wang X2, Colman S3
1Amgen Inc., Thousand Oaks, CA, USA, 2Covance Market Access, Gaithersburg, MD, USA, 
3Covance Pty Ltd, North Ryde, Australia
objeCtives: To examine the change in renal function among patients with bone 
metastases (BM) from solid tumors (ST) Methods: A retrospective cohort study 
was conducted using OSCER (Oncology Services Comprehensive Electronic Records) 
database, containing electronic medical records from > 50 outpatient oncology/
hematology practice groups in the US. The study sample included adults (age > = 
18 years) diagnosed with a single ST and BM between 01/01/2012 through 09/30/2013. 
Changes in renal function from baseline (6 months prior to the BM diagnosis) over 
the follow-up period were assessed. The outcomes of interest include clinically-
meaningful increase in serum creatinine (SeCr) [defined as 0.5 mg/dL increase 
in patients with normal baseline levels (< 1.4 mg/dL), and 1.0 mg/dL increase in 
those with elevated baseline levels (≥ 1.4 mg/dL)], estimated glomerular filtration 
rate (eGFR), and chronic kidney disease (CKD) stage (1: eGFR> 90 to 5: eGFR< 15). 
Descriptive analysis was conducted to examine baseline patient characteristics 
and change in renal function. Results: A total of 6,380 patients met the eligibility 
criteria; majority of them were female (52%), Caucasian (70%), with mean age of 67 
years (Standard Deviation [SD]: 12), mean SeCr of 1.0 (SD: 0.5), and mean eGFR of 77 
(SD: 23) at baseline. During a median follow-up of 191 days after BM diagnosis, an 
average 11-point (SD: 17) reduction (relative reduction: 13%) in eGFR from baseline 
was observed. Clinically-meaningful increases in SeCr were observed in 10.8% of 
the patients overall; among 7.2% patients from elevated (n= 706) and 11.3% from 
normal (n= 5,674) baseline SeCr levels. Increases in CKD stage from baseline levels 
were observed in 36% of the patients. ConClusions: Worsened renal function was 
observed among patients with ST and BM. Given the use of bone targeting agents 
in this patient population, future analysis is needed to understand the impact of 
those agents, such as zoledronic acid, on renal function.
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ePideMiOlOgy ANd TreATMeNT Of sOfT TissUe sArCOMA iN The eU5
Robinson D, Nersesyan K, Pomerantz D
Kantar Health, Horsham, PA, USA
objeCtives: Explore the epidemiology and treatment of soft tissue sarcoma (STS) 
in EU5. Methods: Epidemiology of STS was derived from the Kantar Health (KH) 
CancerMPact database, sources for which include country specific cancer regis-
tries, published scientific studies and proprietary physician surveys conducted 
in March 2015 comprising 76 doctors seeing an average of 3,210 STS patients per 
month. Country specific age and gender incidence rates were applied to country 
population data to determine number of newly diagnosed STS patients. Annual 
non-metastatic and metastatic progression rates and annual non-metastatic and 
metastatic survival rates are used to calculate total number of surviving patients 
up to 10 years after diagnosis. Treatment data was determined from the physi-
cian surveys and was country specific. Results: Incidence of STS ranged from 
3.1 – 4.1 per 100K . Among all incident STS patients, 74% were non metastatic and 
16% were metastatic. Surgery/Drug/Radiation rates were, respectively, 43%/37%/19% 
in France, 52%/42%/22% in Germany, 49%/31%/27% in Italy, 41%/34%/29% in Spain 
and 45%/28%/27% in the UK. Among metastatic patients, 41% to 44% received a 
first line drug. There was wide variation in the % of first line that received second 
line (range 35% - 58%) and second line who received third (17% - 30%). Among 
first line drug treated doxorubicin plus ifosfamide was the preferred regimen in 
France, Germany and Spain whereas doxorubicin monotherapy was preferred in UK. 
Trabectedin and pazopanib were used relatively frequently as second or third line 
treatments. ConClusions: This study confirms the rarity of soft tissue sarcoma in 
EU5. Doxorubicin plus ifosfamide is the most commonly used treatment in first line 
across EU5, trabectedin and pazopanib tend to be the most utilized treatments in 
second and third line. Variance to the trend is apparent in France and Spain second 
line and in France and UK third line.
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sysTeMATiC revieW Of bUrdeN Of PANCreATiC CANCer
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
objeCtives: Pancreatic cancer is considered one of the toughest cancers to treat, with 
extremely poor prognosis. The objective of this research was to conduct a systematic 
review of epidemiology and the burden of pancreatic cancer. Methods: A systematic 
literature search for epidemiology and the burden of disease studies was undertaken 
for the databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was 
collected for the study type, methods, country and key findings. Extracted study data 
included pancreatic cancer incidence, complications, mortality, available treatment 
options, as well as healthcare resource utilization and medical costs associated with 
pancreatic cancer. Critical analyses of study quality and data gaps were analyzed at 
the country level. Results: A total of 328 studies were identified based on the key-
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Van den Eertwegh AJ6, Haanen JB5, Van der Hoeven KJ3, Uyl - de Groot CA2
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objeCtives: Ipilimumab improved the survival of advanced melanoma patients in 
phase III trials (MDX010-20 [previously treated patients] and CA184-024 [treatment 
naïve patients]). Uncertainty exists, however, whether this benefit can be translated 
to real-world clinical practice. We investigated the use and survival outcomes of 
ipilimumab in The Netherlands. Methods: We retrieved data from the population-
based Dutch Melanoma Treatment Registry (DMTR). The DMTR includes all Dutch 
patients with unresectable stage IIIc/IV melanoma. Detailed data were prospectively 
collected from start of diagnosis until death or loss to follow-up. Survival outcomes 
(overall survival [OS] and one-year survival) in patients receiving ipilimumab in 
clinical practice were assessed using Kaplan-Meier estimates, and were compared 
with outcomes of pivotal trials and outcomes of real-world patients diagnosed 
before the introduction of ipilimumab (2003-2011; stage IV only) using data from 
the Dutch Comprehensive Cancer Centres. Results: From 2012-2015, 545 patients 
received at least one dose of ipilimumab in real-world practice (65% received four 
dosages; median follow-up 4.6 months; data cut-off March 9, 2015). Ipilimumab 
was most frequently prescribed in the second line (60%), followed by the first (31%), 
third (8%), and fourth line (2%), respectively. Median OS was 7.7 months (IQR:3.6-NR) 
and one-year survival was 40%. This is somewhat lower than in the pivotal trials, 
which may be due to differences in baseline characteristics and time of follow-up 
(MDX010-20: median follow-up 27.8 months, median OS 10.1 months, one-year 
survival 46%; CA184-024: median follow-up 11.0 months, median OS 11.2 months, 
one-year survival 48%). However, the survival was higher compared to the survival 
in the period before the introduction of ipilimumab (2003-2011: median OS 6.8 
months [IQR:3.3-18.5], one-year survival 33%). ConClusions: Melanoma survival 
has improved since the introduction of ipilimumab. Although survival was some-
what lower in real-world compared to pivotal trials, a survival benefit was observed 
in Dutch real-world clinical practice.
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WheN “Alive AfTer 5 yeArs” dOes NOT MeAN “CUred”: iNTerNATiONAl 
PATTerNs iN CANCer 10- TO 20- yeAr relATive sUrvivAl rATes
Martin A, Martin C
Crystallise Ltd., London, UK
objeCtives: Traditionally, patients who survive 5 years from diagnosis of cancer 
are considered to be cured. More recent analysis of adjusted mortality rates sug-
gests this assumption may not be valid. We sought to identify data on relative 
survival at 10 to 20 years for common cancers to determine which showed a 
continuing increase in mortality beyond 5 years. Methods: National or regional 
cancer databases reporting net or relative survival beyond 5 years from diagno-
sis were identified, with 5- and 10-year data available from England and Wales, 
Scotland, the USA, Switzerland and Slovakia; 5-, 10- and 15-year data from Norway; 
and 5-, 10-, 15- and 20-year data from Germany and Sweden. The percentage 
decrease in net survival at each 5-year step was calculated at 10, 15 and 20 years 
to identify where there was a persistent increase in all-cause mortality above 
expected for the age- and sex-adjusted cancer-free population. Results: Regional 
setting had a large impact on relative survival for each type of cancer. However, 
oropharyngeal, head and neck, liver, lung, pancreatic and ovarian cancers, chronic 
lymphocytic leukaemia, mesothelioma, multiple myeloma, and Kaposi’s sarcoma 
consistently showed between a 10% and 70% further decrease in relative survival 
at 10 compared with 5 years. A further 10% or greater decrease in relative sur-
vival was seen between 10 and 20 years from diagnosis for head and neck, lung, 
laryngeal and prostate cancer, and was around 40% lower than population norms 
at 20 years for people with multiple myeloma. ConClusions: When modelling 
the impact of treatments for cancer, it is important to consider the whole period 
of increased risk of mortality. For certain cancers, in particular multiple myeloma, 
lung, prostate and laryngeal cancer, this may require a time horizon of 20 years 
or longer.
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objeCtives: New drugs for advanced melanoma showed promising results in piv-
otal trials; however, uncertainty exists regarding their value in real-world clinical 
practice. We investigated real-world treatment patterns and outcomes of advanced 
melanoma in The Netherlands. Methods: We retrieved data from the population-
based Dutch Melanoma Treatment Registry (DMTR). The DMTR includes all Dutch 
patients with unresectable stage IIIc/IV melanoma. Detailed data were prospectively 
collected from start of diagnosis until death or loss to follow-up. Real-world treat-
ment patterns and outcomes (overall survival [OS], one-year survival and time-to-
next-treatment [TTNT]) were assessed in patients receiving systemic treatment 
Weights (IPCW), and Iterative Parameter Estimation (IPE). To determine acceptance 
of these techniques in Australia, Public Summary Documents (PSDs) reporting on the 
Pharmaceutical Benefits Advisory Committee’s (PBAC’s) decision-making in oncol-
ogy were reviewed. Methods: Oncology PSDs were examined, and the method of 
adjustment (if any), PBAC concerns and outcome were assessed. Results: Thirty-
one submissions included trials allowing crossover; 16 (52%) presented adjusted 
estimates of OS. Common indications were: renal cell carcinoma, non-small cell 
lung cancer (NSCLC), melanoma, colorectal cancer (CRC), and pancreatic neuroendo-
crine tumour. The most common method was RPSFT (11 products), followed by IPCW 
(4 products). IPE, marginal structural modelling, and a two-stage Weibull approach 
were each reported once. The RPSFT approach appeared to raise fewer concerns 
than the IPCW, usually because the IPCW correction was considered less reliable 
when a high proportion of patients crossed-over. In NSCLC and CRC, the PBAC con-
sidered unadjusted crossover to be appropriate and reflect a relevant comparison 
between first- and second-line therapy. Only five PSDs reported results of more 
than one method. The PBAC expressed a preference to see a range of approaches 
and a clearly justified selection of the most appropriate method. ConClusions: A 
range of adjustment techniques were used to support submissions in Australia, with 
RPSFT being most common. It is important to clearly justify the need for adjustment 
and the selection of the most appropriate technique.
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sAfeTy ANd iNsUrANCe PreMiUM iMPliCATiONs fOr hOsPiTAls bAsed ON 
sUbCUTANeOUs versUs iNTrAveNOUs AdMiNisTrATiON Of ONCOlOgy / 
heMATOlOgy TherAPies: CAse sTUdies WiTh riTUxiMAb (MAbTherA) ANd 
TrAsTUzUMAb (herCePTiN)
Walzer S1, Era S2, Profico A2, Canciani M3, Farina M3, Ponzetti C4
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di Monza, Montalto Dora, Italy
objeCtives: In oncology an important parameter of safety is the potential treat-
ment error in hospitals. The hypothesis which is being analyzed in the underlying 
work is the potential benefit of hospitals from a safety reduction through fix-
dose ready to use subcutaneous therapies in comparison to intravenous therapies 
with trastuzumab and rituximab. Methods: For the calculation of risk levels the 
Failure Mode and Effect Analysis (FMEA) approach was being applied. Within that 
approach the critical treatment path is followed and risk classification for each 
individual step is being estimated. For the oncology and hematology administra-
tion there were 35 different risk steps assessed. The study was executed in 17 
hematology and 16 breast cancer centers in Italy. Results: When the risk classes 
are calculated there were eight high risk areas identified for the administration 
of an intravenous therapy in hematology or oncology, 13 areas would be defined 
as having a median risk and 14 areas as having a low risk classification (total risk 
areas: n= 35). When the new subcutaneous formulation would be applied 23 dif-
ferent risk levels could be completely eliminated (65% reduction). Including those 
eliminations important high risk classes such as the following were included: 
dose calculation, preparation and package labeling, preparation of the access to 
the vene and pump infusion preparation and infusion monitoring. The overall risk 
level for the intravenous administration was estimated to be 756 (ex-ante) and 
could be significantly reduced by 70% (ex-post). The potential harm compensation 
for errors related to the pharmacy would be decreased from 234’271 € for eight 
risk classes to only 3 risk classes. ConClusions: The use of a subcutaneous 
administration of trastuzumab (breast cancer) and rituximab (hematology) might 
lower the risk of administration and treatment errors for patients and could hence 
indirectly have a positive financial impact for hospitals.
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objeCtives: There is a paucity of study to examine the relationship between 
metformin use and hepatocellular carcinoma (HCC) specific survival or recur-
rence. We, therefore, conducted a nationwide population-based study in the 
patients with HCC who underwent curative resection to investigate whether 
metformin use would reduce mortality and recurrence rate. Methods: The 
study population initially included 105,367 adults who had a primary diagno-
sis of HCC (International Classification of Diseases, 10th revision, C22) from the 
Korea Center Cancer Registry between 1 January 2005 and 31 December 2011. 
The primary outcome was HCC-specific survival. We obtained HCC deaths from 
the National Population Registry of the Korea National Statistical Office through 
December 31, 2013, with the use of a unique personal identification number. The 
secondary outcome was tumor recurrence during follow-up periods from National 
Health Insurance Service. Results: The HCC-related survival or recurrence-free 
was significantly higher in the metformin user group than in the metformin non-
user group during the follow-up period. In unadjusted analyses, compared to 
non-metformin group, metformin group showed a significant lower risk of HCC-
specific death (hazard ratio (HR), 0.40; 95% Confidence interval (CI), 0.32-0.51). 
After multivariable adjustments for clinical covariates, metformin group still had 
a significantly lower risk of events as compared with non-metformin group (HR, 
0.38; 95% CI, 0.30-0.49). The adjusted risk for recurrence was also significantly 
lower in metformin group (HR, 0.41; 95% CI, 0.33-0.52) compared with that of non-
metformin group. ConClusions: Among patients of HCC cohort treated with 
curative hepatic resection, metformin use was associated with improvement of 
HCC-specific mortality and recurrence risk.
